Kurzfassung

A 24-week with possible extention, prospective, multicentre, randomized, double-blind, placebo-controlled, 2-parallel group with a randomization 1:1, Phase III study to compare efficacy and safelty of masitinib at 6 mg/kg/day to placeco in treatment of patients with Smouldering Systemic, Indolent Systemic or Cutaneous Mastocytosis with handicap